Cannabinoid Receptor 1, CT, Control Peptide (CB1)

Control Peptide for C1075-71 (affinity purified antibody) and C1075-71F (antiserum).\n\nCannabinoids, a group of C21 compounds present in Cannabis sativa L.. Their carboxylic acids, analogs and transformation products are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affect cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive. It impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two subtypes of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. CB1 (rat/mouse 473aa, human 472aa, ~95% sequence homology) has 7 TM domains with an extracellular N-terminus and cytoplasmic C-terminus. An alternative spliced N-terminal variant, CB1A, has also been reported. The CB1 receptor has been shown to inhibit adenylate cyclase activity in a pertussis-toxin sensitive manner and to be more responsive to psychoactive cannabinoids than to non-psychoactive cannabinoids. CB1 couples to a pertussis-toxin sensitive G-protein to regulate Ca2+ currents, to activate inward rectifying K+ channels and to activate MAP Kinases. CB1 receptor is distributed throughout the brain, with higher representation in the hippocampus, a brain region essential for storage of newly acquired information and changes of mood and behavioral state. In the cerebellum, CB1 is most dense in the molecular layer, consistent with the effects of cannabinoids on the coordination of motor function and motor learning. Outside the CNS, CB1 expression is found in testes, endothelial cells and ileum longitudinal smooth muscle.\n\nApplications:\nSuitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.\n\nRecommended Dilution: \nAntibody Blocking: Use 5-10ug per 1ug of affinity purified antibody (C1075-71) or 1ul of antiserum (C1075-71F).\nELISA: 50-100ng control peptide per well.\nOptimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nLyophilized powder is stable for at least 12 months at -20 degrees C Reconstituted product must be stored in aliquots at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C1075-71A

Size

100ug

Applications

ELISA

Reactivities

Rat

Form

Supplied as a lyophilized powder in PBS, pH 7.5, 0.05% sodium azide.\nReconstitute with 100ul sterile dH2O.

Purity

Highly Purified

References

1. Gerard, C.M., et al., Biochem. J. 279: 129-134 (1991). 2. Gerard, C.M., et al., Nucl. Acid Res. 18: 7142 (1990). 3. Shire, D., et al., J. Biol. Chem. 270: 3726-3731 (1995). 4. Matsuda, L.A., et al., Nature 346: 561-564 (1990). 5. Ho, B.Y., et al., Neurosci. Lett. 212: 123-126 (1996). 6. Chakraborty, A., et al., DNA seq. 5: 385-388 (1995).

Additional Info

Synthetic peptide 20aa sequence near the cytoplasmic, C-terminus of rat CB1. No significant sequence homology exists with CV2 or other receptors. Species crossreactivity: Rat. Species sequence homology (Expected Crossreactivity): Mouse: 100%; monkey and human: 94%; zebra finch: (88%; feline and salamander: 75%; puffer fish: 73%.